By Bill Shingleton, Cell and Gene Therapy Biology Director, Cytiva
Patient cells are the foundations for cell and gene therapies, products that are increasing in quantity and in their diverse treatment applications. However, cell and gene therapy supply chains introduce specific challenges that differ from those associated with biologics. The development, manufacturing, and transport of cell and gene therapies require consideration and care, including temperature controls and tracking and verifying the chain of custody.
Collaborative efforts and automated solutions will be critical to help lead the changes to produce cell and gene therapies to meet market and patient demand. This will allow the industry to take a step back from the reliance on manual and time-consuming laboratory-based methods.